KV9.3 Antibody (D-11): sc-365497

KV9.3 Antibody (D-11) is a mouse monoclonal IgG2b antibody that detects KV9.3 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). KV9.3 is a crucial component of voltage-gated potassium channels, which play a vital role in controlling the repolarization and frequency of action potentials in excitable cells, including neurons and muscle cells. KV9.3 (D-11) antibody recognizes a protein that localizes to the cellular membrane and is predominantly expressed in the lung, with minimal expression in peripheral blood lymphocytes. KV9.3 functions by reducing ion flow and modulating the activity of potassium channels, which is essential for maintaining the electrical excitability of cells. Understanding the expression and function of KV9.3 is critical for elucidating its role in various physiological processes and potential pathophysiological conditions, making anti-KV9.3 antibody (D-11) an invaluable tool for researchers studying ion channel dynamics and their implications in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

KV9.3 Antibody (D-11) References:

1. Kv2.1/Kv9.3, an ATP-dependent delayed-rectifier K+ channel in pulmonary artery myocytes.  |  Patel, AJ., et al. 1999. Ann N Y Acad Sci. 868: 438-41. PMID: 10414317
2. Fluorescence measurements reveal stoichiometry of K+ channels formed by modulatory and delayed rectifier alpha-subunits.  |  Kerschensteiner, D., et al. 2005. Proc Natl Acad Sci U S A. 102: 6160-5. PMID: 15827117
3. Analysis of voltage-gated potassium channel beta1 subunits in the porcine neonatal ductus arteriosus.  |  Hayama, E., et al. 2006. Pediatr Res. 59: 167-74. PMID: 16439573
4. Stromatoxin-sensitive, heteromultimeric Kv2.1/Kv9.3 channels contribute to myogenic control of cerebral arterial diameter.  |  Zhong, XZ., et al. 2010. J Physiol. 588: 4519-37. PMID: 20876197
5. Silencing of voltage-gated potassium channel KV9.3 inhibits proliferation in human colon and lung carcinoma cells.  |  Lee, JH., et al. 2015. Oncotarget. 6: 8132-43. PMID: 25924237
6. Modulation of Closed-State Inactivation in Kv2.1/Kv6.4 Heterotetramers as Mechanism for 4-AP Induced Potentiation.  |  Stas, JI., et al. 2015. PLoS One. 10: e0141349. PMID: 26505474
7. Comparison of Voltage Gated K+ Currents in Arterial Myocytes with Heterologously Expressed K v Subunits.  |  Cox, RH. and Fromme, S. 2016. Cell Biochem Biophys. 74: 499-511. PMID: 27638047
8. Determining the correct stoichiometry of Kv2.1/Kv6.4 heterotetramers, functional in multiple stoichiometrical configurations.  |  Möller, L., et al. 2020. Proc Natl Acad Sci U S A. 117: 9365-9376. PMID: 32284408
9. Kcns3 deficiency disrupts Parvalbumin neuron physiology in mouse prefrontal cortex: Implications for the pathophysiology of schizophrenia.  |  Miyamae, T., et al. 2021. Neurobiol Dis. 155: 105382. PMID: 33940180
10. Kv2.1/Kv9.3, a novel ATP-dependent delayed-rectifier K+ channel in oxygen-sensitive pulmonary artery myocytes.  |  Patel, AJ., et al. 1997. EMBO J. 16: 6615-25. PMID: 9362476

The preferred KV9.3 antibody is KV9.3 Antibody (D-6): sc-365979.